We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 06. | 장 마감 후 (AMC) | — | — | — | — | — | 예정 |
| FY2023 Q3 | 2022. 09. 30. | 시각 미정 | — | $-2.11 | — | — | $0 | 보고됨 |
| FY2023 Q2 | 2022. 06. 30. | 시각 미정 | — | $-1.42 | — | — | $0 |
Rating & price-target changes
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2025. 08. 13. | JMP Securities | — | 투자의견 하향 | Market Outperform → Market Perform | — | JMP Securities: Market Outperform → Market Perform |
| 2025. 03. 31. | Citizens Capital Markets | — | 의견 유지 | Market Outperform → Market Outperform | — | Citizens Capital Markets: Market Outperform |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2023 Q1 | 2022. 03. 31. | 시각 미정 | — | $-0.65 | — | — | $0 | 보고됨 |
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 81,330 | $46.17M | 0.00% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
Stored first · Google News · Yahoo Finance (English)
BioAtla Inc. (BCAB) Slips Nearly 3% as Biotech Sector Faces Headwinds - Profitability Factor - thelegaladvocate.com
BioAtla Inc. (BCAB) Slips Nearly 3% as Biotech Sector Faces Headwinds - Profitability Factor thelegaladvocate.com
BCAB Technical Analysis | Trend, Signals & Chart Patterns | BIOATLA INC (NASDAQ:BCAB) - ChartMill
BCAB Technical Analysis | Trend, Signals & Chart Patterns | BIOATLA INC (NASDAQ:BCAB) ChartMill
BCAB Stock Price, Quote & Chart | BIOATLA INC (NASDAQ:BCAB) - ChartMill
BCAB Stock Price, Quote & Chart | BIOATLA INC (NASDAQ:BCAB) ChartMill
BioAtla Inc. (BCAB) Edges Higher as Stock Tests Key Resistance Near $3.95 - Schiff Line - thelegaladvocate.com
BioAtla Inc. (BCAB) Edges Higher as Stock Tests Key Resistance Near $3.95 - Schiff Line thelegaladvocate.com
BioAtla (BCAB) Q4 2025 Earnings: EPS $-8.00 Beats Estimates - Strong Earnings Momentum - thelegaladvocate.com
BioAtla (BCAB) Q4 2025 Earnings: EPS $-8.00 Beats Estimates - Strong Earnings Momentum thelegaladvocate.com
BioAtla (BCAB) Q4 2025 Earnings: EPS $-8.00 Beats Estimates - Basic EPS Analysis - newsline.com
BioAtla (BCAB) Q4 2025 Earnings: EPS $-8.00 Beats Estimates - Basic EPS Analysis newsline.com